Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
McKinsey
Harvard Business School
Dow

Last Updated: May 28, 2022

Sebela Ireland Ltd Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SEBELA IRELAND LTD, and what generic alternatives to SEBELA IRELAND LTD drugs are available?

SEBELA IRELAND LTD has seventeen approved drugs.

There are eleven US patents protecting SEBELA IRELAND LTD drugs.

There are eighty-three patent family members on SEBELA IRELAND LTD drugs in thirty-six countries and two supplementary protection certificates in two countries.

Summary for Sebela Ireland Ltd
International Patents:83
US Patents:11
Tradenames:12
Ingredients:10
NDAs:17

Drugs and US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990 AB RX Yes Yes See Plans and Pricing See Plans and Pricing
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes 8,778,365 See Plans and Pricing Y See Plans and Pricing
Sebela Ireland Ltd MICORT-HC hydrocortisone acetate CREAM;TOPICAL 040398-001 Mar 29, 2002 DISCN No No See Plans and Pricing See Plans and Pricing
Sebela Ireland Ltd IMURAN azathioprine TABLET;ORAL 016324-002 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 8,591,948 See Plans and Pricing
Sebela Ireland Ltd RIDAURA auranofin CAPSULE;ORAL 018689-001 May 24, 1985 4,225,597 See Plans and Pricing
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 5,874,447 See Plans and Pricing
Sebela Ireland Ltd LOTRONEX alosetron hydrochloride TABLET;ORAL 021107-001 Feb 9, 2000 5,360,800 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SEBELA IRELAND LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 7.5 mg ➤ Subscribe 2014-04-07
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-12-02

Supplementary Protection Certificates for Sebela Ireland Ltd Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom See Plans and Pricing PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498 10C0038 France See Plans and Pricing PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.